Ampio Pharma (AMPE) – StreetInsider.com Reports
-
Ampio Pharma (AMPE) Announces Voluntary Delisting
-
Ampio Pharma (AMPE) Provides Update on Results from Pre-IND Enabling Studies
-
Ampio Pharma (AMPE) Files $50M Mixed Shelf
-
Ampio Pharma (AMPE) Announces 1:20 Reverse Stock Split
-
Ampio Pharma (AMPE) Issues Letter to Shareholders
-
Ampio Pharma (AMPE) CEO Issues Letter to Shareholders
-
Ampio Pharma (AMPE) Announces NYSE American Removal of Trading Suspension
-
Ampio Pharma (AMPE) Announces 15:1 Reverse Stock Split
-
Ampio Pharma (AMPE) Issues Letter to Shareholders
-
Ampio Pharma (AMPE) Issues Letter to Stockholders, Calls for Reverse Stock-split
-
Ampio Pharma (AMPE) Announces NYSE American Has Commenced Delisting Proceedings
-
Ampio Pharma (AMPE) halted, news pending
-
Ampio Pharma (AMPE) CEO Issues Letter to Shareholders
-
Ampio Pharma (AMPE) Granted US Patent #11369598 for "TREATMENT OF T-CELL MEDIATED DISEASES" Patent Stocks
-
Ampio Pharma (AMPE) CEO Issues Letter to Shareholders
-
Ampio Pharma (AMPE) Announces Independent Committee to Conduct Investigation
-
Ampio Pharmaceuticals (AMPE) PT Lowered to $2 at Roth Capital
-
Ampio Pharma (AMPE) receives written responses from FDA pursuant to Type C meeting request regarding AP-013 trial results
-
Ampio Pharma (AMPE) Reports Q4 Net Loss of $6.2M
-
Pre-Open Stock Movers 03/24: (AMPE) (IRBT) (OXM) Higher; (COOK) (RMED) (OKTA) Lower
-
Ampio Pharma (AMPE) Surges 60% Following New Buy Rating
-
Alliance Global Partners Starts Ampio Pharmaceuticals (AMPE) at Buy
-
Ampio Pharma (AMPE) Reports Positive Phase 3 Data Analysis for Ampion
-
Ampio Pharma (AMPE) Appints Elizabeth Varki Jobes to its Board
-
Ampio Pharma's (AMPE) CEO Mike Martino Issues Letter to Stockholders
-
Pre-Open Stock Movers 12/13: (ARNA) (FHTX) (HOG) Higher; (NISN) (TXMD) (AMPE) Lower (more...)
-
Ampio Pharma (AMPE) Prices 25M Direct Share and Warrant Offering at $0.90/sh
-
Ampio Pharma (AMPE) Announces Board Member Michael Martino to Become Interim Chairman and CEO, Mike Macaluso to Take Medical Leave
-
Ampio Pharma (AMPE) Reports Q3 Loss of $0.02/sh
-
Ampio Pharma (AMPE) Appoints Howard Levy as Chief Medical Officer; J. Kevin Buchi and Michael Martino to Company's Board
-
Ampio Pharma (AMPE) Receives Approval from the Drugs Controller General of India to Commence AP-019 Phase II Study in India
-
Ampio Pharma (AMPE) Announces Positive Top-line Phase 3 Results of AP-013 in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)
-
Ampio Pharma (AMPE) Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action
-
Ampio Pharma (AMPE) Reports In-Line Q2 EPS
-
Ampio Pharma (AMPE) Provides Update on Osteoarthritis of the Knee Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK
-
Pre-Open Stock Movers 06/15: (CLSD) (OCGN) (AMPE) Higher; (PDSB) (PTGX) (PING) Lower (more...)
-
Ampio Pharma (AMPE) Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India
-
Ampio Pharma (AMPE) Reports In-Line Q1 EPS
-
Ampio Pharma (AMPE) Announces Ampion Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%
-
Ampio Pharma (AMPE) Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19
-
Ampio Pharma (AMPE) Says Research Shows Ampion Gene Regulation Mimics Anti-Inflammatory Effects of Steroids, but without Adverse Effects
-
Ampio Pharma's (AMPE) Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis
-
Ampio Pharma (AMPE) Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory Distress
-
Ampio (AMPE) Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion
-
Ampio Pharma (AMPE) Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in COVID-19 Respiratory Distress
-
Ampio Pharma (AMPE) Reports 55% Enrollment in Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion (AP-014)
-
Ampio Pharma (AMPE) Provides Update on Clinical Trials for Ampion Treatment of COVID-19 Patients
-
Ampio Pharma (AMPE) Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion
-
Ampio Pharma (AMPE) Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress
-
Ampio Pharma (AMPE) Updates Regulatory and Clinical Trial Events
Back to AMPE Stock Lookup